Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics is expected to see a positive future, with a market value of approximately $814 million by the end of 2026, taking into consideration their projected cash reserves and investments. The company's prospects are deemed favorable, with potential success in their program FT819 for SLE and risks such as safety and regulatory concerns, partnership risks, and dilution in the medium-term. Hence, this company has potential for long-term growth and can present a good investment opportunity.

Bears say

Fate Therapeutics is facing a negative outlook due to its lack of diversity in its pipeline and high-risk experimental treatments in the clinical stage. Additionally, the company's financials may be impacted by its extensive investment in research and development, which may not yield positive results in the future. Furthermore, the company's focus on treating autoimmune disorders with immunotherapies may also face regulatory challenges, leading to potential delays in bringing products to market.

Fate Therapeutics (FATE) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 3 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.